Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso Sells 1,526 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 1,526 shares of Precision BioSciences stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $10.32, for a total transaction of $15,748.32. Following the completion of the transaction, the chief executive officer now owns 13,772 shares in the company, valued at approximately $142,127.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Precision BioSciences Stock Performance

Shares of NASDAQ:DTIL opened at $10.52 on Friday. Precision BioSciences, Inc. has a 52 week low of $8.25 and a 52 week high of $27.02. The firm has a 50 day simple moving average of $12.55 and a 200 day simple moving average of $11.79.

Precision BioSciences (NASDAQ:DTIL) last released its earnings results on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.00 by ($6.35). Precision BioSciences had a negative net margin of 125.84% and a negative return on equity of 204.66%. The business had revenue of $7.04 million during the quarter, compared to analysts’ expectations of $28.50 million. As a group, analysts expect that Precision BioSciences, Inc. will post -3.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DTIL has been the subject of several research reports. Guggenheim began coverage on Precision BioSciences in a research note on Tuesday. They set a “buy” rating and a $19.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research note on Wednesday, April 17th.

Institutional Investors Weigh In On Precision BioSciences

A number of institutional investors have recently bought and sold shares of the business. Curi Wealth Management LLC increased its holdings in shares of Precision BioSciences by 42.0% in the 3rd quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock valued at $116,000 after purchasing an additional 100,530 shares during the period. Tejara Capital Ltd boosted its holdings in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares during the period. Finally, Acadian Asset Management LLC grew its position in Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock valued at $1,073,000 after purchasing an additional 242,425 shares in the last quarter. 37.99% of the stock is currently owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.